

USA

4819 Emperor Boulevard
Suite 400
Durham, North Carolina 27703
919-313-4760 (Phone)
919-313-4700 (Fax)

CANADA

3001 12th Avenue North
Sherbrooke, (Québec) J1H 5N4
819-820-6840 (Phone)
819-820-6841 (Fax)

www.tranzyme.com

e-mail: contact@tranzyme.com

RECENT HIGHLIGHTS

December 2009 Tranzyme Pharma Enters into Strategic Drug Discovery Collaboration with Bristol-Myers Squibb

July 2009 Tranzyme Pharma Receives FDA Fast Track Status for Its Oral GI Prokinetic Drug Candidate TZIP-102

June 2009 Tranzyme Pharma CEO Vipin Garg Wins Ernst and Young Entrepreneur of the Year Award

May 2009 Tranzyme Pharma Initiates Dosing in Ph2 Study with Oral Ghrelin Agonist TZIP-102 in Patients with Gastroparesis

April 2009 Tranzyme Pharma Announces Positive Ph2 Results with TZIP-101 for Gastroparesis

March 2009 Tranzyme Pharma Announces Issuance of 3 New Patents Further Strengthening Company's Advanced Ghrelin Agonist Programs

October 2008 Tranzyme Pharma's Ghrelin Agonist TZIP-101 Shows Potential as a Potent Agent for Cancer Cachexia

October 2008 Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZIP-101 for Postoperative Ileus (POI)

tranzyme[®]
pharma

AT A GLANCE

MECHANISM-BASED THERAPEUTICS

Tranzyme Pharma is a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics for the treatment of both acute (hospital-based) and chronic disorders with significant unmet medical needs. The Company's current product pipeline is derived from its proprietary MATCH™ technology platform and targets two validated GPCR drug targets: ghrelin and motilin. The ghrelin receptor is responsible for upper gut motility, appetite regulation and energy balance, and the motilin receptor is associated with the general regulation of GI transit. Tranzyme is developing three novel small molecule compounds targeting the ghrelin receptor and one compound aimed at the motilin receptor. TZIP-101 and TZIP-102 are ghrelin agonists and TZIP-301 is a ghrelin antagonist. TZIP-101 is an intravenously administered prokinetic agent that has been successfully studied in two international Phase 2b trials, one for the management of postoperative ileus (POI) and a second for the treatment of gastroparesis in acute settings. TZIP-101 is poised to enter Phase 3 in the near term. TZIP-102 is an orally-administered prokinetic agent that shares the potent prokinetic attributes of TZIP-101 while being a chemically distinct molecule, and is aimed at treating gastroparesis and selected potential additional indications such as GERD, functional dyspepsia, OBD, and cancer cachexia. TZIP-102 is currently being evaluated in a multi-national Phase 2 study. TZIP-301, for the treatment of obesity and metabolic syndrome, and TZIP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea, are advancing through preclinical development.




Product Development Pipeline

Name	Indications	Current Status	Future Milestones
TZIP-101 (i.v.) <i>ghrelin agonist</i>	<ul style="list-style-type: none">Post-operative ileus (POI)Gastroparesis in acute settings	Phase 2b (completed) Phase 2b (completed)	Phase 3 Phase 3
TZIP-102 (oral) <i>ghrelin agonist</i>	<ul style="list-style-type: none">Chronic gastroparesisGERD (+/- PPIs)Functional dyspepsia	Phase 1 (completed) Phase 2 (ongoing)	Complete Phase 2
TZIP-201 <i>motilin antagonist</i>	<ul style="list-style-type: none">Moderate-to-severe diarrhea such as chemotherapy-induced diarrhea (CID)Irritable bowel syndrome (diarrhea type) (IBS-d)	Preclinical	IND
TZIP-301 <i>ghrelin antagonist</i>	<ul style="list-style-type: none">ObesityMetabolic syndrome	Preclinical	IND

NOVEL SMALL MOLECULE DRUG DISCOVERY TECHNOLOGY

Tranzyme's pipeline of products originates from its proprietary **Macrocylic Template Chemistry (MATCH™)**. MATCH™ is a drug design and medicinal chemistry platform which exploits the potential of macrocycles, a distinct compound class that displays the favorable characteristics exhibited by large biomolecules, while maintaining the benefits typically associated with small molecule drugs. Outside of Tranzyme's current development focus, MATCH™ has broad applicability in the treatment of other diseases that involve hormones, peptides, ion channels or protein-protein interaction pathways.



July 2008 Tranzyme Pharma Receives Notices of Allowance from USPTO on Two Patents Protecting Company's Lead Pharmaceutical Development Programs

June 2008 Tranzyme Pharma Announces Successful Thorough QT/QTc Study of Ghrelin Agonist TZP-101

June 2008 Tranzyme Pharma Demonstrates Favorable Pharmacokinetics in its Successful Completion of a Phase I Trial with its Oral Ghrelin Agonist, TZP-102

June 2008 Tranzyme Pharma's Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the Successful Completion of a Phase I Trial

OUR INVESTORS

Tranzyme Pharma is supported by an international consortium of investors from the U.S., Canada and Japan.

- BDC Venture Capital
- Desjardins Venture Capital
- H.I.G. Ventures
- Pacific Rim Ventures
- Quaker BioVentures
- Thomas, McNerney & Partners

WHO TO CONTACT

Richard Eisenstadt, MBA
VP, Finance & CFO
Phone: (919) 313-4762
reisenstadt@tranzyme.com

Jennifer Filbey
VP, Business Development
Phone: (256) 417-8568
jfillbey@tranzyme.com

Susan Josselyn
Corporate Communications Mgr
Phone: (919) 313-4761
sjosselyn@tranzyme.com

PARTNERING STRATEGY

Tranzyme's strategy is to license certain rights to its drug development programs once proof of concept in man is achieved, or when a program may benefit from the research, development and commercialization capabilities of a partner. Through these strategic partnerships, Tranzyme intends to balance risk while preserving the potential for significant returns.

MANAGEMENT TEAM

Tranzyme Pharma has assembled an experienced management and R&D team to implement clinical and corporate programs. The collective pharmaceutical industry experience of Tranzyme's management includes drug development in relevant disease areas from discovery all the way to market launch, negotiating drug development partnerships and licenses, and taking product-focused companies to IPO.

Vipin K. Garg, Ph.D.
President & CEO

Experience: Curacyte, DNX, Sepracor, BioResponse (Baxter)

Helmut Thomas, Ph.D., DABT
SVP, Research & Preclinical Development

Experience: LymphoSign, Novartis, CIBA Pharmaceuticals

Gordana Kosutic, M.D.
VP, Clinical & Regulatory Affairs

Experience: Fulcrum Pharma, Nobex Corp., ClinTrials, ICN Pharmaceuticals

Mark Peterson, Ph.D.
VP, Intellectual Property & Operations

Experience: Monsanto, Advanced ChemTech

Richard Eisenstadt, MBA
VP, Finance & CFO

Experience: Cogent Neuroscience, Nimbus CD International

Jennifer A. Filbey, Ph.D.
VP, Business Development

Experience: Hoechst, Nobex, Nektar Therapeutics

FACILITIES

The Company maintains U.S. and Canadian operations. The North Carolina site serves as the corporate headquarters and the center for business development, clinical development and regulatory activities. The medicinal chemistry, lead optimization and preclinical development activities are based in Quebec.